Peer-reviewed veterinary case report
Gastrointestinal and blood side effects in dogs after lymphoma chemo
By Tomiyasu, Hirotaka et al.·Published in The Journal of veterinary medical science·2010·Department of Veterinary Internal Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Gastrointestinal and hematologic adverse events after administration of vincristine, cyclophosphamide, and doxorubicin in dogs with lymphoma that underwent a combination multidrug chemotherapy protocol.
- Species:
- dog
Plain-English summary
A group of 40 dogs with lymphoma received a combination of chemotherapy drugs, including vincristine, cyclophosphamide, and doxorubicin, as part of a treatment protocol. During the treatment, about half of the dogs experienced gastrointestinal issues like vomiting or diarrhea, and over half had blood-related problems. The most common side effects occurred after the first dose of vincristine. Understanding these potential side effects can help pet owners and veterinarians manage treatment better and prepare for any complications that may arise.
People also search for: dog lymphoma chemotherapy side effects · vincristine adverse effects in dogs · dog blood problems after chemotherapy
Abstract
The present study aimed to objectively evaluate the adverse events after the administration of chemotherapeutic agents used in the University of Wisconsin (UW)-Madison chemotherapy protocol (UW-25) for canine lymphoma, using the Veterinary Co-operative Oncology Group common terminology criteria for adverse events (VCOG-CTCAE). The medical records of 40 dogs with multicentric high-grade lymphoma that underwent UW-25 were reviewed. Gastrointestinal adverse events of grade 2 and above and blood/bone marrow adverse events of all grades were evaluated. Gastrointestinal adverse events occurring at least once during the entire period of UW-25 were observed in 50% (20/40), 17.9% (7/39), and 8.1% (3/37) of the dogs after the administration of vincristine (VCR), cyclophosphamide (CPA), and doxorubicin (DXR), respectively. Blood/bone marrow adverse events occurring at least once during UW-25 were observed in 57.5% (23/40), 41% (16/39), and 8.1% (3/37) of the dogs after the administration of VCR, CPA, and DXR, respectively. The rate of patients that experienced gastrointestinal adverse events was higher after the first administration of VCR than after the first administration of DXR. Findings obtained in this study will be helpful in predicting the adverse events that could occur when dogs with lymphoma are treated with UW-25.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20543531/